研究業績

消化器内科

消化器内科業績

  1. Oishi S, Takano R, Tamura S, Tani S, Iwaizumi M, Hamaya Y, Takagaki K, Nagata T, Seto S, Horii T, Osawa S, Furuta T, Miyajima H, Sugimoto K: M2 polarization of murine peritoneal macrophages induces regulatory cytokine production and suppresses T-cell proliferation, Immunology, 149(3), 320-328, 2016.
  2. Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, Sugimoto K, Carethers JM: Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status, Cancer Biol Ther, 17(7), 760-768, 2016.
  3. Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T: Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype, Aliment Pharmacol Ther, 43(10), 1048-1059, 2016.
英文業績
  1. Oishi S, Takano R, Tamura S, Tani S, Iwaizumi M, Hamaya Y, Takagaki K, Nagata T, Seto S, Horii T, Osawa S, Furuta T, Miyajima H, Sugimoto K: M2 polarization of murine peritoneal macrophages induces regulatory cytokine production and suppresses T-cell proliferation, Immunology, 149(3), 320-328, 2016.
  2. Suzuki S, Iwaizumi M, Tseng-Rogenski S, Hamaya Y, Miyajima H, Kanaoka S, Sugimoto K, Carethers JM: Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status, Cancer Biol Ther, 17(7), 760-768, 2016.
  3. Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T: Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype, Aliment Pharmacol Ther, 43(10), 1048-1059, 2016.
  4. Ichikawa H, Sugimoto M, Sakao Y, Sahara S, Ohashi N, Kato A, Sugimoto K, Furuta T, Andoh A, Sakao T, Yasuda H:Relationship between ghrelin, Helicobacter pylori and gastric mucosal atrophy in hemodialysis patients, World JGastroenterol, 22(47), 10440-10449, 2016.
  5. Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T: Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis, J Gastroenterol Hepatol, 31(4), 716-726, 2016.
  6. Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Kagami T, Iwaizumi M, Hamaya Y, Osawa S, Sugimoto K,Umemura K: Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis. 2017 Apr;43(3):333-342
  7. Mori M, Genda T, Ichida T, Murata A, Kamei M, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Ishikawa S, Kikuchi T, Shimada Y, Hirano K, Iijima K, Sugimoto K, Wada R, Nagahara A, Watanabe S: Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk, Hepatol Res, 47(3), E85-E93, 2017.
  8. Yamada T, Sugimoto K: Guggulsterone and Its Role in Chronic Diseases, Adv Exp Med Biol, 929, 329-361, 2016.
  9. Takagaki K, Osawa S, Ito T, Iwaizumi M, Hamaya Y, Tsukui H, Furuta T, Wada H, Baba S, Sugimoto K: Inverted Meckel's diverticulum preoperatively diagnosed using double-balloon enteroscopy, World J Gastroenterol, 22(17), 4416-4420, 2016.
 
邦文総説など
  1. 杉本健: IBDに対する抗体薬治療のポイント－カルプロテクチン, ラクトフェリンを含めた糞便マーカーをどのように使っていくべきか? IBD Research, 10(4), 218-223, 2016.
  2. 杉本健: 潰瘍性大腸炎に対するアダカラム(GMA) の有効性の再確認と免疫学的作用機序, 新薬と臨牀, 65(7), 999-1000, 2016.
  3. 岩泉守哉、椙村春彦:　遺伝性腫瘍研究・腫瘍各論　家族性胃がん　遺伝子医学MOOK　別冊（最新遺伝性腫瘍・家族性腫瘍研究と遺伝カウンセリング）202-206,2016.
  4. 杉本健: 血球成分除去療法の進め方, IBDを日常診療で診る〜炎症性腸疾患を疑うべき症状と、患者にあわせた治療法, 羊土社 東京: 124-128, 2017.

一覧に戻る